APPENDIX A

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No. 266; Mannitol dry powder for inhalation for treating cystic fibrosis, and NICE Technology Appraisal No. 276; Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Companies • Forest Laboratories (colistimethate sodium powder for inhalation) • Novartis Pharmaceuticals (tobramycin powder and podhaler) • Pharmaxis Pharmaceuticals (mannitol powder for inhalation) • PH&T Pharma (Turbospin inhaler for use with colistimethate sodium powder) Patient/carer groups • Action for Sick Children • Afiya Trust • Black Health Agency • British Lung Foundation • Contact a Family • Cystic Fibrosis Trust • Equalities National Council • Genetic Alliance • Jewish Genetic Disorders UK • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • South Asian Health Foundation • Specialised Healthcare Alliance • Together for Short Lives Professional groups • Association of Chartered Physiotherapists in Respiratory Care • Association of Genetic Nurses & Counsellors • Association of Respiratory Nurse	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Comparator manufacturers • Forest Laboratories (colistimethate sodium for nebulised inhalation) • Novartis (tobramycin for nebulised inhalation) • Profile Pharma (colistimethate sodium for nebulised inhalation) Relevant research groups • British Association for Lung Research • Cochrane Airways Group • Cochrane Cystic Fibrosis & Genetic Disorders Group • MRC Clinical Trials Unit • National Institute for Health Research • UK Cystic Fibrosis Gene Therapy

Specialists • British Geriatrics Society • British Paediatric Respiratory Society • British Society for Genetic Medicine • British Thoracic Society • Chartered Society of Physiotherapy • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <u>Others</u> • Department of Health • NHS England • Welsh Government • NHS Wolverhampton CCG • NHS Lewisham CCG	Consortium <u>Assessment Group</u> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Clinical Guideline Centre • National Collaborating Centre for Women and Children's Health <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).
All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.
All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.